Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery. In this episode, we discuss: How LLMs expand the scope of machine learning from rule-based tasks to open-ended reasoning and dialogueWhy healthcare adoption is tiered, beginning with clinician-facing AI scribes and moving toward patient-facing companies...
All content for Business Trip is the property of Greg Kubin & Matias Serebrinsky and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery. In this episode, we discuss: How LLMs expand the scope of machine learning from rule-based tasks to open-ended reasoning and dialogueWhy healthcare adoption is tiered, beginning with clinician-facing AI scribes and moving toward patient-facing companies...
Temporal Interference: The Future of Brain Stimulation with Nir Grossman
Business Trip
22 minutes
9 months ago
Temporal Interference: The Future of Brain Stimulation with Nir Grossman
Greg and Matias interview Dr. Nir Grossman, one of the world’s leading researchers in neurotechnology. Nir is a lecturer in the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute. In this episode, we discuss: What is temporal interference (TI), a non-invasive stimulation methodA comparison of TI with deep brain stimulation (DBS)How physics plays a crucial role in neuroscience innovationTranslating TI academic research to c...
Business Trip
Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery. In this episode, we discuss: How LLMs expand the scope of machine learning from rule-based tasks to open-ended reasoning and dialogueWhy healthcare adoption is tiered, beginning with clinician-facing AI scribes and moving toward patient-facing companies...
